secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2025-10-24T23:59:59+00:00
Accession:  0001104659-25-102004
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aprea reports 3 of 4 patients with stable disease at 100 mg APR-1051 in Phase 1 trial
--------------------------------------------------------------------------------

- 3 of 4 heavily pretreated patients achieved stable disease (RECIST v1.1) at 100 mg dose level.
- Disease stabilization observed in tumors with FBXW7, CCNE1, KRAS G12V, TP53 mutations.
- No dose-limiting toxicities reported; dose escalation continues at 150 mg cohort.
- Poster presented at AACR-NCI-EORTC conference on Oct 24, 2025; data cutoff Sep 17, 2025.
- Individual responses: rectal cancer patient on 145 days of treatment with -13% reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000110465925102004/0001104659-25-102004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000110465925102004/apre-20251024x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-102004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer